SAN DIEGO, Oct. 3, 2016 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson & Weaver, LLP, is investigating potential
claims against Cognizant Technology Solutions Corporation, BofI
Holding, Inc, Seres Therapeutics, Inc., SeaWorld Entertainment,
Inc., and ProNAi Therapeutics, Inc., as detailed below.
Cognizant Technology Solutions Corporation
Johnson & Weaver, LLP, is investigating potential violations
of the federal securities laws by Cognizant Technology Solutions
Corporation (NASDAQ:CTSH) and certain of its officers.
On September 30, 2016, Cognizant made
known that it was conducting an internal investigation into whether
certain payments in India violated
the U.S. Foreign Corrupt Practices Act. Cognizant also announced
that its president had resigned. On this news, shares of Cognizant
closed down sharply on September 30,
2016.
If you have information that could assist in this
investigation, including past employees and others, or if you are a
Cognizant shareholder and are interested in learning more about the
investigation or your legal rights and remedies, please contact
Jim Baker
(jimb@johnsonandweaver.com) by email or phone at 619-814-4471.
If emailing, please include a phone number where you can be
reached.
BofI Holding, Inc.
Johnson & Weaver, LLP is investigating potential violations
of federal and state laws by BofI Holding, Inc.
(NASDAQ: BOFI) and certain of its officers. A class action
lawsuit against the Company has been filed on behalf of
shareholders who purchased BofI stock between September 4, 2013 through October 13, 2015, (the "Class Period").
According to the complaint, Defendants made false and misleading
statements and failed to disclose that: (1) BofI's internal
controls were frequently disregarded; (2) BofI's borrowers included
foreign nationals who should have been off-limits under federal
anti-money-laundering laws; (3) many BofI accounts lacked required
tax identification numbers; (4) BofI fired an internal auditor who
raised these issues to management and to federal regulators; and
(5) as a result of the above, BofI's statements regarding its
internal controls and other financial statements were materially
false and misleading at all relevant times.
If you have held BofI shares continuously prior to
September 4, 2013, you may
have standing to hold BofI harmless from the damage the officers
and directors caused by making them personally responsible. You may
also be able to assist in reforming the Company's corporate
governance to prevent future wrongdoing.
If you are a BofI shareholder and are interested in learning
more about the investigation or your legal rights and remedies,
please contact lead analyst Jim
Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you
email, please include your phone number.
Seres Therapeutics, Inc.
Johnson & Weaver, LLP is investigating potential violations
of the federal securities laws by Seres Therapeutics, Inc.
(NASDAQ:MCRB) and certain of its officers. On July 29, 2016 Seres announced that its 8-week
results from the ongoing SER-109 Phase 2 ECOSPOR™ clinical study
for the prevention of multiply recurrent Clostridium
difficile infection ("CDI") did not meet the primary endpoint
of reducing the relative risk of CDI recurrence. On this news, the
price of Seres' stock plummeted 69%. Two days before the
announcement, on July 27, 2016,
Seres' President, Chief Executive Officer, and Chairman of the
Board (Roger Pomerantz) sold 20,000
shares at much higher prices. Another senior executive, on
that same day, sold 38,064 shares at $35.1285 per share for gross proceeds of
$1,337,510.
If you are a long-term, continuous holder of Seres
stock, you may have standing to hold Seres harmless from the
damage the officers and directors caused by making them personally
responsible. You may also be able to assist in reforming the
Company's corporate governance to prevent future
wrongdoing.
If you are a Seres shareholder and are interested in learning
more about the investigation or your legal rights and remedies,
please contact lead analyst Jim
Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you
email, please include your phone number.
SeaWorld Entertainment, Inc.
Johnson & Weaver, LLP is investigating potential violations
of federal and state laws by SeaWorld Entertainment, Inc.
(NYSE: SEAS) and certain of its officers. A class action
lawsuit against the Company was filed on behalf of shareholders who
purchased SeaWorld between August 29,
2013 and August 12, 2014, (the
"Class Period").
The complaint filed in the class action lawsuit alleges that
SeaWorld and certain of its officers and directors made false and
misleading statements and failed to disclose information regarding
the critically acclaimed 2013 documentary Blackfish – a film which
the complaint alleges had a profound impact on attendance at
SeaWorld-branded parks throughout the Class Period, as it damaged
the public's perception of SeaWorld and degraded the Company's core
brand and business. On September 29,
2016, the Court issued a tentative ruling denying
defendants' motion to dismiss the federal class action.
If you have held SeaWorld shares continuously prior to
December 2013, you may have
standing to hold SeaWorld harmless from the damage the officers and
directors caused by making them personally responsible. You may
also be able to assist in reforming the Company's corporate
governance to prevent future wrongdoing.
If you are a SeaWorld shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact lead analyst Jim
Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you
email, please include your phone number.
ProNAi Therapeutics, Inc.
Johnson & Weaver, LLP is investigating potential violations
of the federal securities laws by ProNAi Therapeutics, Inc.
(NASDAQ: DNAI) and certain of its officers. On July 16, 2015, ProNAi's stock traded as high as
$33.75, the same day the Company sold
8.1 million shares of stock in its initial public stock offering
(the "IPO"), raising $137.7 million
in new capital. However, since the IPO, ProNAi's stock has tumbled,
closing at $1.82 on September 30, 2016.
On June 6, 2016, ProNAi released
its interim results from the Wolverine Phase 2 trial of PNT2258 for
the treatment of relapsed or refractory (r/r) diffuse large B-cell
lymphoma (DLBCL). Nick Glover,
President and CEO said, "Although [PNT2258] observed modest
efficacy …in [the] interim analysis of Wolverine," the Company has
"decided to suspend the development of PNT2258" because the results
were not "robust enough to justify continued development of the
drug in DLBCL." Specifically, Johnson & Weaver's investigation
seeks to determine whether certain statements regarding the
Company's business metrics and financial prospects were not as
strong as represented in the Registration
Statement.
If you are a ProNAi shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact lead analyst Jim
Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you
email, please include your phone number.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder
rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonandweaver.com. Attorney advertising. Past results
do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--weaver-llp-initiates-investigations-of-cognizant-technology-solutions-corporation-bofi-holding-inc-seres-therapeutics-inc-seaworld-entertainment-inc-and-pronai-therapeutics-inc-encourages-long-term-investor-300337930.html
SOURCE Johnson & Weaver, LLP